Robert J. Henkel
Known title: DirectorCIK: 0001789650
Robert J. Henkel's purchase track record
How the stock did after each of Robert J. Henkel's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since September 13, 2021
Stock higher 6 months later
40%
3 months: 80%
Median 6-month return
-10.9%
3 months: +12.8%
Beat the S&P 500
40%
median -23.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/17/2022 | ACH | $16K | +25.1% | -10.9% | +12.9% |
| 7/15/2022 | ACH | $32K | -52.0% | -36.8% | +3.5% |
| 5/2/2022 | ACH | $70K | +2.9% | -52.2% | -6.8% |
| 10/15/2021 | ACH | $33K | +34.4% | +31.0% | -1.8% |
| 9/13/2021 | ACH | $35K | +12.8% | +10.8% | -6.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ACH | ▲ Buy | Grant | 28,914 | $0 | 5/15/2025 | View on chart |
| ACH | ▲ Buy | Grant | 11,154 | $0 | 5/9/2024 | View on chart |
| ACH | ▲ Buy | Grant | 9,344 | $0 | 5/12/2023 | View on chart |
| ACH | ▲ Buy | Open Market | 1,000 | $16K | 10/17/2022 | View on chart |
| ACH | ▲ Buy | Open Market | 1,000 | $32K | 7/15/2022 | View on chart |
| ACH | ▲ Buy | Open Market | 2,000 | $70K | 5/2/2022 | View on chart |
| ACH | ▲ Buy | Open Market | 1,000 | $33K | 10/15/2021 | View on chart |
| ACH | ▲ Buy | Open Market | 1,000 | $35K | 9/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Accendra Health Receives NYSE Continued Listing Notice
Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.
Accendra Health Receives NYSE Continued Listing Notice. Accendra Health received a notice from the NYSE regarding continued listing standards, with the company stating its intent to cure the deficiency. This regulatory development adds pressure to a stock that is already trading near its 52-week low. Additionally, Bank of America disclosed a 10.8% stake in the company as of September 30.